The safety of 52 weeks of oral DHEA therapy for postmenopausal women.

[1]  Heng-hui Cheng,et al.  Dehydroepiandrosterone anti-atherogenesis effect is not via its conversion to estrogen , 2009, Acta Pharmacologica Sinica.

[2]  Jenny Adams,et al.  Methodology and challenges to recruitment to a randomized, double-blind, placebo-controlled trial of oral DHEA in postmenopausal women. , 2008, Journal of women's health.

[3]  S. Davis,et al.  DHEA therapy for women: effect on sexual function and wellbeing. , 2007, Human reproduction update.

[4]  R. Bérubé,et al.  Metabolism of DHEA in postmenopausal women following percutaneous administration , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[5]  P. Bélanger,et al.  Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women , 2006, The Journal of Steroid Biochemistry and Molecular Biology.

[6]  M. Seif,et al.  Testosterone for peri- and postmenopausal women. , 2005, The Cochrane database of systematic reviews.

[7]  S. Davis,et al.  Androgen levels in adult females: changes with age, menopause, and oophorectomy. , 2005, The Journal of clinical endocrinology and metabolism.

[8]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[9]  A. Genazzani,et al.  Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids. , 2003, Fertility and sterility.

[10]  J. Simard,et al.  Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. , 2003, Endocrine reviews.

[11]  Dongmin Liu,et al.  Dehydroepiandrosterone Activates Endothelial Cell Nitric-oxide Synthase by a Specific Plasma Membrane Receptor Coupled to Gαi2,3 * , 2002, The Journal of Biological Chemistry.

[12]  D. Cucinotta,et al.  Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. , 2001, European journal of endocrinology.

[13]  W. Kohrt,et al.  Effects of DHEA replacement on bone mineral density and body composition in elderly women and men , 2000, Clinical endocrinology.

[14]  G. Chatellier,et al.  Dehydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. , 2000, The Journal of clinical endocrinology and metabolism.

[15]  S. Puccetti,et al.  Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause , 2000, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[16]  B. Allolio,et al.  Dhea Replacement in Women with Adrenal Insufficiency—Pharmacokinetics, Bioconversion and Clinical Effects on Well-Being, Sexuality and Cognition , 2000, Endocrine research.

[17]  K. Barnhart,et al.  The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. , 2000, The Journal of clinical endocrinology and metabolism.

[18]  K. Barnhart,et al.  The effect of deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life , 1999 .

[19]  M. Bidlingmaier,et al.  Dehydroepiandrosterone replacement in women with adrenal insufficiency. , 1999, The New England journal of medicine.

[20]  N. Santoro,et al.  Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial. , 1998, Fertility and sterility.

[21]  J. Simard,et al.  DHEA and the Intracrine Formation of Androgens and Estrogens in Peripheral Target Tissues: Its Role during Aging , 1998, Steroids.

[22]  J. Goméz,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Effect of 12-Month Dehydroepiandrosterone Replacement Therapy on Bone, Vagina, and Endometrium in Postmenopausal Women , 2022 .

[23]  S. Davis,et al.  Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. , 1997, The New England journal of medicine.

[24]  F. Labrie,et al.  Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women , 1996 .

[25]  W. Zgliczyński,et al.  Hyperinsulinaemia and decreased plasma levels of dehydroepiandrosterone sulfate in premenopausal women with coronary heart disease , 1995, Journal of internal medicine.

[26]  A. Morales.  Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age [published erratum appears in J Clin Endocrinol Metab 1995 Sep;80(9):2799] , 1994 .

[27]  S. Yen,et al.  Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. , 1994, The Journal of clinical endocrinology and metabolism.

[28]  S. Yen,et al.  The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. , 1990, The Journal of clinical endocrinology and metabolism.

[29]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.